The characterization of peritoneal and pleural exudate cells from malignant effusions

M Oka1, S Yoshino, S Hazama

  • 1Second Department of Surgery, Yamaguchi University School of Medicine, Japan.

Surgery Today
|January 1, 1993
PubMed

Insights

Immune cells in cancer effusions show reduced cytotoxic and NK cell activity, with increased suppressor T-cells. Local interleukin-2 administration can induce lymphokine-activated killer (LAK) cells, suggesting a dual approach for effective immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Patients with advanced cancer often exhibit altered immune cell function.
  • Malignant effusions can harbor immune cells with distinct characteristics compared to peripheral blood.

Purpose of the Study:

  • To compare the immune function of cells from malignant effusions with peripheral blood cells.
  • To investigate lymphocyte subsets, natural killer (NK) cell activity, and anti-Daudi and lymphokine-activated killer (LAK) cell activity.

Main Methods:

  • Analysis of lymphocyte subsets (CD4+, CD8+CD11+, CD8+CD11-) in peripheral blood mononuclear cells (PBMC) and effusion cells (PEC).
  • Measurement of NK cell activity and anti-Daudi activity in PBMC and PEC.
  • Induction of LAK cells by culturing with interleukin-2 (IL-2).

Main Results:

  • Higher percentage of CD4+ cells in PEC compared to PBMC.
  • Increased suppressor T-cells (CD8+CD11+) in PEC and PBMC of patients; cytotoxic T-cells (CD8+CD11-) were similar.
  • Lower NK activity in PEC than PBMC; anti-Daudi activity was markedly low in PEC.
  • High LAK cell activity was inducible from PEC with IL-2.

Conclusions:

  • Immune cells in malignant effusions may have depressed function due to low cytotoxic T-cells, low NK activity, and increased suppressor T-cells.
  • Local IL-2 administration can induce LAK cells in malignant effusions.
  • Effective immunotherapy for malignant effusions requires augmenting effector cells and inhibiting suppressor cells.